Pharmsville Co. Ltd
Pharmsville Co., Ltd. produces and sells functional health food in South Korea. The company also exports its products. It offers its products under the Apple Tree Dr. Kim, Devil Diet, Sang Sang Bang, Vitamin Story, Apple Tree, Golden Garden, Daily Green, Wilac, Doctor Solution, and PS brands. Pharmsville Co., Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
Pharmsville Co. Ltd (318010) - Net Assets
Latest net assets as of September 2025: ₩65.92 Billion KRW
Based on the latest financial reports, Pharmsville Co. Ltd (318010) has net assets worth ₩65.92 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩68.51 Billion) and total liabilities (₩2.58 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩65.92 Billion |
| % of Total Assets | 96.23% |
| Annual Growth Rate | 19.03% |
| 5-Year Change | 15.93% |
| 10-Year Change | N/A |
| Growth Volatility | 36.25 |
Pharmsville Co. Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Pharmsville Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pharmsville Co. Ltd (2017–2024)
The table below shows the annual net assets of Pharmsville Co. Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩64.52 Billion | +0.95% |
| 2023-12-31 | ₩63.91 Billion | +2.16% |
| 2022-12-31 | ₩62.56 Billion | +5.68% |
| 2021-12-31 | ₩59.20 Billion | +6.37% |
| 2020-12-31 | ₩55.65 Billion | +0.45% |
| 2019-12-31 | ₩55.40 Billion | +105.83% |
| 2018-12-31 | ₩26.92 Billion | +41.26% |
| 2017-12-31 | ₩19.06 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharmsville Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 125.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩40.19 Billion | 62.29% |
| Common Stock | ₩3.96 Billion | 6.14% |
| Other Components | ₩20.37 Billion | 31.57% |
| Total Equity | ₩64.52 Billion | 100.00% |
Pharmsville Co. Ltd Competitors by Market Cap
The table below lists competitors of Pharmsville Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Great Divide Mining Ltd
AU:GDM
|
$4.71 Million |
|
Utility Business Alliance PCL
BK:UBA
|
$4.71 Million |
|
A-Smart Holdings Ltd.
F:IOTA
|
$4.72 Million |
|
SMD100_SAINTMED
BK:SMD100
|
$4.72 Million |
|
Crown Lifters Limited
NSE:CROWN
|
$4.70 Million |
|
Phapros Tbk PT
JK:PEHA
|
$4.70 Million |
|
Timberwell Bhd
KLSE:7854
|
$4.70 Million |
|
Free Flow Inc
OTCQB:FFLO
|
$4.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharmsville Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 63,913,663,380 to 64,521,894,120, a change of 608,230,740 (1.0%).
- Net income of 1,583,025,840 contributed positively to equity growth.
- Dividend payments of 774,988,900 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.58 Billion | +2.45% |
| Dividends Paid | ₩774.99 Million | -1.2% |
| Other Changes | ₩-199.81 Million | -0.31% |
| Total Change | ₩- | 0.95% |
Book Value vs Market Value Analysis
This analysis compares Pharmsville Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.41x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩7939.59 | ₩3435.00 | x |
| 2018-12-31 | ₩10681.34 | ₩3435.00 | x |
| 2019-12-31 | ₩6987.23 | ₩3435.00 | x |
| 2020-12-31 | ₩7093.03 | ₩3435.00 | x |
| 2021-12-31 | ₩7544.87 | ₩3435.00 | x |
| 2022-12-31 | ₩7973.30 | ₩3435.00 | x |
| 2023-12-31 | ₩8247.04 | ₩3435.00 | x |
| 2024-12-31 | ₩8348.98 | ₩3435.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharmsville Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.47%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.04x
- Recent ROE (2.45%) is below the historical average (9.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 19.25% | 21.83% | 0.58x | 1.52x | ₩1.76 Billion |
| 2018 | 17.98% | 24.40% | 0.59x | 1.24x | ₩2.15 Billion |
| 2019 | 13.10% | 24.22% | 0.44x | 1.22x | ₩1.72 Billion |
| 2020 | 5.20% | 7.34% | 0.57x | 1.24x | ₩-2.67 Billion |
| 2021 | 8.45% | 12.81% | 0.53x | 1.26x | ₩-920.07 Million |
| 2022 | 6.49% | 15.56% | 0.35x | 1.20x | ₩-2.19 Billion |
| 2023 | 5.18% | 15.47% | 0.30x | 1.12x | ₩-3.08 Billion |
| 2024 | 2.45% | 9.47% | 0.25x | 1.04x | ₩-4.87 Billion |
Industry Comparison
This section compares Pharmsville Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharmsville Co. Ltd (318010) | ₩65.92 Billion | 19.25% | 0.04x | $4.71 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |